Results 161 to 170 of about 44,899 (264)

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics‐Based Biomarkers

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Interindividual variability in drug pharmacokinetics and susceptibility to drug–drug interactions remain major barriers in precision dosing, particularly for narrow therapeutic index drugs. While genetic factors contribute, much variability arises from dynamic influences such as physiology, disease, age, diet, microbiome, and concomitant ...
Bhagwat Prasad
wiley   +1 more source

CARACTERIZACIÓN DE VARIANTES ALÉLICAS DE CITOCROMO CYP2D6 EN LA POBLACIÓN DE LA REGIÓN CENTROCCIDENTAL DE VENEZUELA

Acta Biológica Colombiana, 2009
RESUMEN El gen CYP2D6 codifica para una monooxigenasa perteneciente al citocromo P450, la cual está involucrada en la biotransformación de un gran número de drogas comúnmente prescritas, como antidepresivos, antineoplásicos y antihipertensivos. Algunos
PEDRO GRIMÁN, YEINMY MORÁN, MARÍA CAMARGO, MIGUEL ANGEL CHIURILLO   +3 more
doaj  

CYP2D6 Gene [PDF]

, 2020
openaire   +1 more source

Opportunities to improve open All of Us data to convey CYP2D6 pharmacological relevance and interpretation overall and according to ancestry. [PDF]

Front Pharmacol
Hendricks-Sturrup RM, Christensen KD, Lu CY.   +2 more
europepmc   +1 more source

Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy. [PDF]

Pharmacogenomics J
Magavern EF, Dan GA, Savarese G, Borghi C, Dobrev D, Tamargo J, Ferdinandy P, McDermott JH, Newman WG, Pirmohamed M, Caulfield MJ, Kaski JC.   +11 more
europepmc   +1 more source

Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study. [PDF]

Pharmacogenomics J
Görnert C, Scherf-Clavel M, Weber H, Roll SC, Eckert A, Reif A, Hahn M.   +6 more
europepmc   +1 more source

Understanding Atomoxetine Exposure Variability in Children and Adolescents With ADHD Through Population Pharmacokinetics. [PDF]

J Clin Pharmacol
Tobin KV, Pritchett A, Leeder JS, Gobburu J, Dunn A.   +4 more
europepmc   +1 more source

CYPRI: a clinical decision-making tool to select psychiatric patients for pharmacogenetic testing. [PDF]

Pharmacogenomics J
Tašková I, Šafářová N, Hahn M.
europepmc   +1 more source

Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study. [PDF]

PLoS Negl Trop Dis
Corder RM, Puça MCSB, Prete CA, Ladeia WA, Rodrigues PT, Johansen IC, de Sousa TN, Ferreira MU, Mâncio Lima Cohort Study Working Group.   +8 more
europepmc   +1 more source

The Effect of <i>CYP2D6</i> Gene Polymorphism on Tramadol Efficacy in Total Knee Arthroplasty. [PDF]

In Vivo
Gürbüz E, Elfiky AA, Ök N, Köseler A.   +3 more
europepmc   +1 more source